Geron Reports 8% RYTELO Revenue Growth in Q1 2026, Strengthens Leadership Team

Event summary

  • RYTELO (imetelstat) net product revenue reached $51.8 million in Q1 2026, an 8% increase from Q4 2025.
  • Geron reiterated its 2026 revenue guidance of $220–240 million and operating expense range of $230–240 million.
  • The company added Timothy Williams as EVP, Chief Legal Officer, and Patricia S. Andrews and Constantine Chinoporos to its Board of Directors.
  • Cash reserves stood at $341 million as of March 31, 2026, down from $401.1 million at year-end 2025.
  • RYTELO was included in the NCCN Chemotherapy Order Templates, positioning it as an active therapeutic for lower-risk myelodysplastic syndromes (LR-MDS).

The big picture

Geron’s Q1 2026 results reflect steady commercial momentum for RYTELO, but its long-term strategy hinges on expanding beyond the U.S. and advancing its Phase 3 IMpactMF trial. The leadership additions suggest a focus on governance and legal strategy as the company navigates regulatory and market challenges. With $341 million in cash reserves, Geron has runway to execute, but execution risks remain in scaling operations and securing European approvals.

What we're watching

Commercial Expansion
Whether Geron can sustain RYTELO revenue growth in the U.S. while successfully entering the European market by year-end.
Clinical Progress
The pace at which investigator-sponsored and real-world evidence trials yield data, potentially expanding RYTELO’s use cases.
Financial Discipline
How Geron balances investment in RYTELO’s supply chain and clinical trials against its operating expense targets.